CAR-T cell therapy
This page covers all CAR-T cell therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor-associated antigen (specific target depends on formulation), CD19, Tumor-associated antigens (specific target antigen not specified).
Targets
Tumor-associated antigen (specific target depends on formulation) · CD19 · Tumor-associated antigens (specific target antigen not specified) · Tumor-associated antigen (specific target not publicly disclosed in detail) · PD-1 · Mesothelin (MSLN) · BCMA (B-cell maturation antigen) · Tumor-associated antigens (e.g., CD19, BCMA, mesothelin depending on construct) · BCMA · CD7
Marketed (3)
- Relma-cel · Shanghai Ming Ju Biotechnology Co., Ltd. · Oncology
Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. - cART · LI Taisheng · Oncology
cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. - IL-7/IL-15 pre-treated CD19 cells · jiangjingting · Oncology
IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.
Phase 3 pipeline (14)
- Liso-cel · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Oncology
Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19. - Low-dose CAR-T cells group · Guangzhou Women and Children's Medical Center · Oncology
Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity. - BMS-986353 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Oncology
BMS-986353 is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. - SCTC21C · Sinocelltech Ltd. · Oncology
SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens. - Injection of C3BS-CQR-1 · Celyad Oncology SA · Oncology
C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens. - PD1-T cells · Tianjin Medical University Cancer Institute and Hospital · Oncology
PD1-T cells are a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. - BMS-986393 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Oncology
BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen. - rondecabtagene autoleucel · Lyell Immunopharma, Inc. · Oncology
Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells. - KITE-753 · Kite, A Gilead Company · Oncology
KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. - bb2121 · Celgene · Oncology
bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA. - CAR T cells · Memorial Sloan Kettering Cancer Center · Oncology
CAR T cells are engineered immune cells that recognize and kill cancer cells by expressing chimeric antigen receptors targeting tumor-associated antigens. - SCTV01E · Sinocelltech Ltd. · Oncology
SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. - High-dose CAR-T cells group · Guangzhou Women and Children's Medical Center · Oncology
High-dose CAR-T cells are engineered immune cells that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens. - CAR-T · Peking University People's Hospital · Oncology
CAR-T cells are engineered T lymphocytes that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens.
Phase 2 pipeline (13)
- CAR-T CD19 · Sheba Medical Center · Oncology
Chimeric antigen receptor T-cell therapy targeting CD19 - DC-CTL · Shenzhen Hornetcorn Bio-technology Company, LTD · Oncology
DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. - Human BCMA Targeted T Cells Injection · Hrain Biotechnology Co., Ltd. · Oncology
BCMA-targeted T cells - Anitocabtagene autleucel · Kite, A Gilead Company · Oncology
Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells. - Cycle 7 Consolidation · Gruppo Italiano Malattie EMatologiche dell'Adulto · Oncology
This drug targets the CD19 protein on B cells to induce cell death. - ARI-0001 cells · Sara V. Latorre · Oncology
ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells. - BCMA CAR-T cells · Chongqing Precision Biotech Co., Ltd · Oncology
BCMA-targeting CAR-T cells - Autologous CD7-targeting CAR T cells · Hebei Senlang Biotechnology Inc., Ltd. · Oncology
Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies. - Cilta-cel OOS Therapy · Janssen Scientific Affairs, LLC · Oncology
Chimeric antigen receptor T-cell therapy - Eque-cel CAR-T Therapy · Nanjing IASO Biotechnology Co., Ltd. · Oncology
CAR-T cell therapy targets CD19-positive B cells - CAR-T-19 cell injection · Beijing Yongtai Ruike Biotechnology Company Ltd · Oncology
CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies. - CD19 t-haNK- IV Administration · ImmunityBio, Inc. · Oncology
CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system. - JCAR017 · Celgene · Oncology
JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.
Phase 1 pipeline (9)
- Anti-CD19 iCAR NK Cells · Allife Medical Science and Technology Co., Ltd. · Oncology
CD19-targeting chimeric antigen receptor (CAR) T cells - Anti-CD22 CAR NK Cells · Allife Medical Science and Technology Co., Ltd. · Oncology
Targeting CD22 on B cells - AIC100 CAR T Cells · AffyImmune Therapeutics, Inc. · Oncology
Chimeric antigen receptor T cells targeting CD19 - Anti-CD5 CAR NK cells · Chongqing Precision Biotech Co., Ltd · Oncology
Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface. - BAFFR CAR-T · Guangzhou Bio-gene Technology Co., Ltd · Oncology
CAR-T cell therapy targeting BAFFR - :Anti-CD22-CAR · Kecellitics Biotech Company Ltd · Oncology
Chimeric antigen receptor targeting CD22 - ATHENA CAR-T · EdiGene Inc. · Oncology
CAR-T cell therapy targeting CD19 - Anti-CD123 CAR NK cells · Chongqing Precision Biotech Co., Ltd · Oncology
CAR-T cell therapy targeting CD123 - AFP Specific T Cell Receptor T Cells · Shanghai Ruiliyuan Biotechnology Co., Ltd. · Oncology
Specific T Cell Receptor T Cells target the AFP antigen